Perspective Therapeutics Shares Fall After Cancer Drug Study Interim Data

Dow Jones

Oct 21, 2025

By Josh Beckerman

Perspective Therapeutics shares declined after it presented updated interim data from an ongoing Phase 1/2a trial of cancer drug VMT-alpha-NET.

The stock was recently down 29% to $3.19 on Monday and is flat for the year to date.

Perspective reported data from the study of patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors. It said the drug "continues to demonstrate durable anti-tumor activity and excellent tolerability."

Perspective said its "remarkable" safety data provides flexibility in dosing as the company advances its clinical development.

Wedbush noted favorable aspects of the results including the drug's safety profile. Oppenheimer said it anticipated the results were "likely to disappoint the Street."

Perspective also updated its cash position and cash runway. The company said its preliminary Sept. 30 cash, cash equivalents and short-term investments balance was about $174.1 million. The company expects this balance to be sufficient to fund its current planned operations and capital investments into late 2026.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

October 20, 2025 15:53 ET (19:53 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2577898138"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577898138\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577898138?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-21 03:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577898138","market":"us","top_or_hot":-1,"title":"Perspective Therapeutics Shares Fall After Cancer Drug Study Interim Data","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CATX\">Perspective Therapeutics</a> shares declined after it presented updated interim data from an ongoing Phase 1/2a trial of cancer drug VMT-alpha-NET. \n</p>\n<p>\n  The stock was recently down 29% to $3.19 on Monday and is flat for the year to date. \n</p>\n<p>\n  Perspective reported data from the study of patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors. It said the drug \"continues to demonstrate durable anti-tumor activity and excellent tolerability.\" \n</p>\n<p>\n  Perspective said its \"remarkable\" safety data provides flexibility in dosing as the company advances its clinical development. \n</p>\n<p>\n  Wedbush noted favorable aspects of the results including the drug's safety profile. Oppenheimer said it anticipated the results were \"likely to disappoint the Street.\" \n</p>\n<p>\n  Perspective also updated its cash position and cash runway. The company said its preliminary Sept. 30 cash, cash equivalents and short-term investments balance was about $174.1 million. The company expects this balance to be sufficient to fund its current planned operations and capital investments into late 2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 20, 2025 15:53 ET (19:53 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Perspective Therapeutics Shares Fall After Cancer Drug Study Interim Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPerspective Therapeutics Shares Fall After Cancer Drug Study Interim Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-21 03:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/CATX\">Perspective Therapeutics</a> shares declined after it presented updated interim data from an ongoing Phase 1/2a trial of cancer drug VMT-alpha-NET. \n</p>\n<p>\n  The stock was recently down 29% to $3.19 on Monday and is flat for the year to date. \n</p>\n<p>\n  Perspective reported data from the study of patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors. It said the drug \"continues to demonstrate durable anti-tumor activity and excellent tolerability.\" \n</p>\n<p>\n  Perspective said its \"remarkable\" safety data provides flexibility in dosing as the company advances its clinical development. \n</p>\n<p>\n  Wedbush noted favorable aspects of the results including the drug's safety profile. Oppenheimer said it anticipated the results were \"likely to disappoint the Street.\" \n</p>\n<p>\n  Perspective also updated its cash position and cash runway. The company said its preliminary Sept. 30 cash, cash equivalents and short-term investments balance was about $174.1 million. The company expects this balance to be sufficient to fund its current planned operations and capital investments into late 2026. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 20, 2025 15:53 ET (19:53 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2577898138","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577898138","pubTimestamp":1760989980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Perspective Therapeutics shares declined after it presented updated interim data from an ongoing Phase 1/2a trial of cancer drug VMT-alpha-NET.The stock was recently down 29% to $3.19 on Monday and is flat for the year to date.Perspective reported data from the study of patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors. It said the drug \"continues to demonstrate durable anti-tumor activity and excellent tolerability.\". Perspective said its \"remarkable\" safety data provides flexibility in dosing as the company advances its clinical development.Wedbush noted favorable aspects of the results including the drug's safety profile. Oppenheimer said it anticipated the results were \"likely to disappoint the Street.\". Perspective also updated its cash position and cash runway. The company said its preliminary Sept. 30 cash, cash equivalents and short-term investments balance was about $174.1 million. The company expects this balance to be suff","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CATX":"Perspective Therapeutics"},"translate_title":"癌症药物研究中期数据公布后，Perspective Therapeutics股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CATX":1.5},"content_text":"By Josh Beckerman \n\n\n \n\n\nPerspective Therapeutics shares declined after it presented updated interim data from an ongoing Phase 1/2a trial of cancer drug VMT-alpha-NET. \n\n\n  The stock was recently down 29% to $3.19 on Monday and is flat for the year to date. \n\n\n  Perspective reported data from the study of patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors. It said the drug \"continues to demonstrate durable anti-tumor activity and excellent tolerability.\" \n\n\n  Perspective said its \"remarkable\" safety data provides flexibility in dosing as the company advances its clinical development. \n\n\n  Wedbush noted favorable aspects of the results including the drug's safety profile. Oppenheimer said it anticipated the results were \"likely to disappoint the Street.\" \n\n\n  Perspective also updated its cash position and cash runway. The company said its preliminary Sept. 30 cash, cash equivalents and short-term investments balance was about $174.1 million. The company expects this balance to be sufficient to fund its current planned operations and capital investments into late 2026. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 20, 2025 15:53 ET (19:53 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}